Novartis Exercises Option to Develop and Market Conatus’ Emricasan to Treat NASH
Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis
Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed in December 2016, Novartis will obtain the license ... Read more